Aravive Forecasted Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Aravive.

Key information

19.8%

Earnings growth rate

31.7%

EPS growth rate

Biotechs earnings growth16.4%
Revenue growth rate-32.3%
Future return on equityn/a
Analyst coverage

Low

Last updated22 Aug 2023

Recent future growth updates

Recent updates

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Apr 26
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Sep 03
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Aravive Q2 GAAP EPS misses, revenue beats

Aug 11

Aravive appoints Robert Geller as CMO

Jul 05

We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

May 15
We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Nov 06
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Jun 25
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive EPS beats by $0.01, misses on revenue

May 06

Aravive shares rise after dosing first patient in late-stage ovarian cancer study

Apr 27

Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Mar 18
Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Feb 09
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive: Pipeline-In-A-Pill In Oncology

Dec 28

Aravive (ARAV) Investor Presentation - Slideshow

Dec 04

Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative

Nov 19

Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater China

Nov 10

Earnings and Revenue Growth Forecasts

NasdaqGS:ARAV - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20251-24-583
12/31/20242-23N/A73
12/31/20234-70N/A-413
6/30/20239-77-69-69N/A
3/31/202310-113-70-70N/A
12/31/20229-76-65-65N/A
9/30/20229-60-59-59N/A
6/30/20226-56-49-49N/A
3/31/20228-44-35-35N/A
12/31/20217-39-32-32N/A
9/30/202112-30-20-20N/A
6/30/202110-30-17-17N/A
3/31/20216-28-18-18N/A
12/31/20206-31-12-12N/A
9/30/2020N/A-31-21-21N/A
6/30/2020N/A-26-19-19N/A
3/31/20203-24-20-20N/A
12/31/20195-18-17-17N/A
9/30/20196-65-21-21N/A
6/30/20196-65-23-23N/A
3/31/20193-72-23-23N/A
12/31/20181-76-29-29N/A
9/30/2018406-58-57N/A
6/30/201840-37-78-75N/A
3/31/201840-64-94-90N/A
12/31/201740-85-121-116N/A
9/30/2017N/A-138-101-98N/A
6/30/2017N/A-116-54-53N/A
3/31/2017N/A-101N/A-54N/A
12/31/2016N/A-96N/A-41N/A
9/30/2016N/A-94N/A-38N/A
6/30/2016N/A-87N/A-78N/A
3/31/2016N/A-84N/A-70N/A
12/31/2015N/A-82N/A-69N/A
9/30/2015N/A-78N/A-64N/A
6/30/2015N/A-71N/A-58N/A
3/31/2015N/A-60N/A-54N/A
12/31/2014N/A-83N/A-40N/A
9/30/2014N/A-73N/A-33N/A
6/30/2014N/A-64N/A-27N/A
3/31/2014N/A-59N/A-18N/A
12/31/2013N/A-18N/A-17N/A
9/30/2013N/A-17N/A-17N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARAV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ARAV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ARAV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ARAV's revenue is expected to decline over the next 3 years (-32.3% per year).

High Growth Revenue: ARAV's revenue is forecast to decline over the next 3 years (-32.3% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ARAV's Return on Equity is forecast to be high in 3 years time


Discover growth companies